Target intelligence / Profile preview

Arenavirus envelope glycoprotein complex (GP-C)

Target
GP-C
Molecular classification
Viral glycoprotein complex, Class I viral fusion protein (specifically the GP2 subunit), Other
01

Overview

The Arenavirus envelope glycoprotein complex, commonly known as GP-C, is a viral surface protein essential for virus attachment and membrane fusion during host cell entry. It comprises three noncovalently associated subunits: GP1 (receptor binding), GP2 (membrane fusion), and a unique stable signal peptide (SSP; ~58 amino acids, myristoylated). Upon synthesis, the precursor GP-C is cleaved by cellular enzymes into its subunits, followed by glycosylation critical for folding and transport. Structural studies show that GP2 adopts a typical class I fusion protein architecture after pH-induced conformational change in the endosome, driving fusion of the viral and host membranes. GP1 binds host receptors (e.g., α-dystroglycan for Old World arenaviruses), but New World arenaviruses use different—and sometimes poorly characterized—receptors. The GP complex is the primary target of the neutralizing antibody response and the main component of experimental vaccines directed against arenavirus infections. The diversity and metastability of the GP1-GP2 interface pose challenges for the development of broadly protective immunogens and therapeutics.

Other names
Arenavirus GP complexArenavirus glycoprotein precursor (GPC)GP1-GP2-SSP complexEnvelope GP complex
02

Mechanism of action

Inhibition of viral entry (antibodies or entry inhibitors bind GP1/GP2 and prevent host cell attachment/fusion); Neutralization (antibodies bind exposed epitopes, block receptor engagement/fusion)

03

Biological functions

Host cell entryMembrane fusionReceptor bindingImmune evasion
04

Disease associations

Infection (viral hemorrhagic fevers caused by arenaviruses: e.g., Lassa fever, Argentine hemorrhagic fever)
05

Safety considerations

Viral mutational escape, leading to resistance to neutralizing antibodiesHigh antigenic variability between arenavirus speciesPotential for antibody-dependent enhancement in some experimental vaccine settings
06

Interacting drugs

Ribavirin (used in some arenavirus infections, though not a direct GP inhibitor)

2 more in the full profile.

07

Biomarkers

Serological detection of anti-GP antibodiesViral glycoprotein complex (as antigen in diagnostic assays)

Beyond the preview

Go deeper on Arenavirus envelope glycoprotein complex (GP-C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arenavirus envelope glycoprotein complex (GP-C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call